At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
Ocrelizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-center Prospective Measurement of Upper Extremity Function in Multiple Sclerosis Patients With Advanced Disability Treated With Ocrevus™
In Brief
An observational study evaluating Ocrelizumab for Multiple Sclerosis and 7 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
The investigators are measuring the effectiveness of Ocrevus™ in helping patients with hand or arm weakness, especially if posed by a more advanced MS patient than those included in the clinical trials.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis, Pathologic Processes, Demyelinating Diseases, Nervous System Diseases, Autoimmune Diseases, Immune System Diseases, Primary Progressive Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedJun 2018
Enrollment StartJul 2018
Primary CompletionJan 2023
TodayJul 2026
First PostedJun 20, 2018
Enrollment StartJul 23, 2018
Primary CompletionJan 11, 2023
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 8.0 years ago
Interventions
Ocrelizumabdrug
Ocrelizumab is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug candidate. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds